Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo

Published:2022-10 Issue: Volume:350 Page:298-307
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Zhou Jing-e,Sun Lei,Jia Yujie,Wang Zhehao,Luo Tengshuo,Tan Jingwen,Fang Xiaoyan,Zhu Hongjia,Wang Jing,Yu Lei,Yan Zhiqiang

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference48 articles.

1. FDA Approves Second CAR T-cell Therapy

2. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy;Fry;Nat. Med.,2018

3. First approval in sight for Novartis’ CAR-T therapy after panel vote;Sheridan;Nat. Biotechnol.,2017

4. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that Progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease;Brudno;J. Clin. Oncol.,2016

5. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia;Fraietta;Blood,2016

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Jump-starting chimeric antigen receptor-T cells to go the extra mile with nanotechnology;Current Opinion in Biotechnology;2024-10

2. Chimeric antigen receptor (CAR) T-cell therapy: Harnessing extracellular vesicles for enhanced efficacy;Pharmacological Research;2024-10

3. Tuning extracellular fluid viscosity to enhance transfection efficiency;Nature Chemical Engineering;2024-09-11

4. Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies;Biomedicine & Pharmacotherapy;2024-09

5. Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies;Blood Reviews;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3